Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer

Wang, Jingpu; Ni, Jie; Beretov, Julia; Thompson, James; Graham, Peter; Li, Yong

doi:10.1016/j.critrevonc.2019.102860

Cited by 88 publications

(46 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although many biomarker tests have been developed during the last ten years, efforts are still placed to improve diagnostic tools aiming to optimize clinical decisions. Recent research showed that the use of micro-RNAs, regulatory non-coding RNAs, circulating tumor cells and exosomes can be promising as biomarkers to differentiate indolent from aggressive PCa [105][106][107]. Other future directions seem to face an approach of combining blood-, urinary-and tissue-based markers with risk calculators in order to select patients for mpMRI and, subsequently, for biopsy.…”

Section: Discussionmentioning

confidence: 99%

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

Visser

Jong

Melchers

et al. 2020

Cancers

View full text Add to dashboard Cite

In the diagnosis and prognosis of prostate cancer (PCa), the serum prostate-specific antigen test is widely used but is associated with low specificity. Therefore, blood-, urinary- and tissue-based biomarker tests have been developed, intended to be used in the diagnostic and prognostic setting of PCa. This review provides an overview of commercially available biomarker tests developed to be used in several clinical stages of PCa management. In the diagnostic setting, the following tests can help selecting the right patients for initial and/or repeat biopsy: PHI, 4K, MiPS, SelectMDx, ExoDx, Proclarix, ConfirmMDx, PCA3 and PCMT. In the prognostic setting, the Prolaris, OncotypeDx and Decipher test can help in risk-stratification of patients regarding treatment decisions. Following, an overview is provided of the studies available comparing the performance of biomarker tests. However, only a small number of recently published head-to-head comparison studies are available. In contrast, recent research has focused on the use of biomarker tests in relation to the (complementary) use of multiparametric magnetic resonance imaging in PCa diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

Visser

Jong

Melchers

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Exosomes are found in various extracellular fluids, thus providing an easily obtained, non-invasive and rapid way for the surveillance of disease progression, as an alternative to tissue biopsy samples. Most studies on exosomes as biomarkers are related to cancer, with specific exosomal proteins identified as being associated with several cancers [61,[71][72][73], even though miRNAs are increasingly investigated as potential biomarkers [74,75]. A major problem is to discriminate informative exosomes -secreted by diseased cells -from the bulk of vesicles (including exosomes and ectosomes).…”

Section: Disease Biomarkersmentioning

confidence: 99%

Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids

Vidal

2020

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Exosomes are 50-100 nm membranous vesicles actively released by cells which can be indicative of a diseased cell status. They contain various kinds of molecule-proteins, mRNA, miRNA, lipids ¬-that are actively being studied as potential biomarkers. Hereafter I put forward several arguments in favor of the potential use of glycosylphosphatidylinositol-anchored proteins (GPI-APs) as biomarkers especially of cancerous diseases. I will briefly update readers on the exosome field and review various features of GPI-APs, before further discussing the advantages of this class of proteins as potential exosomal biomarkers. I will finish with a few examples of exosomal GPI-APs that have already been demonstrated to be good prognostic markers, as well as innovative approaches developed to quantify these exosomal biomarkers. Dear Madam, dear Sir, please, find a review entitled: 'Exosomes and GPI-anchored proteins: judicious pairs for investigating biomarkers from body fluids'. This review chiefly examines the possibility of using exosomal GPIanchored proteins regarding investigation of biomarkers. The aim is to highlight common points in proteins sorted in exosomes while drawing lessons from a cell biology standpoint. One main notion considered is that lipid domains behave as sorting devices during exosomes biogenesis. I believe that this review could be of potential interest to the readership of Advanced drug delivery reviews and more largely to the exosome community, and hope that it will be acceptable for publication. Looking forward to receiving your decision and thanking you for your consideration, Best regards,

show abstract

“…miRNAs play a regulatory role across several biological processes, such as carcinogenesis, inflammation and numerous signaling pathways including the Numb/Notch1 signaling pathway (12,13). miR-31 is associated with the progression of renal cell carcinoma via targeting cyclin-dependent kinase 1 (15).…”

Section: Discussionmentioning

confidence: 99%

“…MicroRNAs (miRNAs/miRs) play a regulatory role in biological processes, including inflammation, by negatively regulating several coding genes (13). miR-31 was demonstrated to be associated with the progress of renal cell carcinoma (RCC) (14).…”

Section: Introductionmentioning

confidence: 99%

Puerarin alleviates cisplatin‑induced acute renal damage and upregulates microRNA‑31‑related signaling

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Cisplatin (DDP) is a commonly used chemotherapy drug; however, the side effects associated with its use, particularly acute kidney injury (AKI), limit its clinical application. Puerarin is a natural flavonoid extracted from the Chinese medical herb Radix puerariae, which has been reported to alleviate DDP-induced nephrotoxicity. However, the mechanisms underlying puerarin regulation on microRNA (miR)-31-mediated signaling pathways in AKI remain unknown. Thus, the present study aimed to investigate the function of puerarin in a DDP-induced AKI rat model via reverse transcription-quantitative PCR and western blot analyses. The results demonstrated that DDP upregulated the levels of miR-31 in a concentration-dependent manner, both in vitro and in vivo. Furthermore, DDP significantly increased blood urea nitrogen and malondialdehyde content, serum creatinine and histopathological changes, while significantly decreasing the expression levels of superoxide dismutase, catalase and glutathione S-transferase in kidney tissues. TUNEL and western blot analyses indicated that DDP increased the expression levels of apoptotic proteins and affected the Numb/Notch1 signaling pathway, which is downstream of miR-31. The effects induced by DDP were counteracted following treatment with puerarin. Taken together, the results of the present study suggest that puerarin exhibits a renal protective effect against DDP-induced AKI by upregulating miR-31 expression and inhibiting the Numb/Notch1 signaling pathway.

show abstract

Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer

Cited by 88 publications

References 112 publications

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids

Puerarin alleviates cisplatin‑induced acute renal damage and upregulates microRNA‑31‑related signaling

Contact Info

Product

Resources

About